Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients with Rheumatoid Arthritis - Oskira ABPM

Study identifier:D4300C00033

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2011-006070-73

CTIS identifier:N/A

Study Complete

Official Title

OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Arthritis

Medical condition

Rheumatoid Arthritis

Phase

Phase 2

Healthy volunteers

No

Study drug

fostamatinib, placebo

Sex

All

Actual Enrollment

266

Study type

Interventional

Age

18 Years - 150 Years

Date

Study Start Date: 01 Apr 2012
Primary Completion Date: 01 Jan 2013
Study Completion Date: 01 Jan 2013

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 May 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria